Innovation that Matters

Filter By


An Interview with Dr. Lawson Macartney, CEO of Ambrx Pharmaceuticals

An interview with Dr. Lawson Macartney, CEO of Ambrx Pharmaceuticals, on the co-development of an ADC therapeutic for HER2-Positive breast for cancer in China.   THE NEWS: This month’s Inside Perspective features Dr. Lawson Macartney, CEO of Ambrx Pharmaceuticals. Ambrx recently announced a deal in which it would co-development a therapeutic for HER2-positive breast cancer with China-based Zhejian Medicine Co. WuXi will handle preclinical, clinical trials and toxin manufacturing. ZMC will hold commercial rights to the compound in China, Ambrx holds rights in the rest of the world, collecting royalties on Chinese sales. QUESTION: Ambrx has an industry-leading ADC technology platform and a number of notable partnerships with western pharmas like Merck and BMS. Why the expansion into China?   Macartney: Accessing the China market is becoming an increasingly important objective within Ambrx. Developing and manufacturing biologics within China to world class standards is a relatively new paradigm. We look forward to integrating these efforts into our global development strategy. QUESTION:From a business perspective, this three-party deal is very creative and intriguing. Could you explain the strategy?  Macartney: This partnership is unique. It allows us to team up with China’s leading pharmaceutical and CRO companies to efficiently access the China market, an opportunity that we would otherwise miss if we were not to combine our respective efforts. This is an innovative deal structure that allows us to gain access to China while also reducing time and R&D costs. QUESTION: What’s one thing you learned putting together this deal that could benefit other companies looking to develop drugs to sell in China? Macartney: Build strong relationships with those that you do business with. This will better enable the collaborations to overcome obstacles and take advantage of opportunities. Related Links: Expediting Development of Biologics in China: From Strategy to Regulatory Expectations and Beyond Ambrx and Zhejiang Medicine Co. Ltd. Form Collaboration to Develop and Commercialize Ambrx’s Antibody Drug Conjugate for Breast Cancer

Read more


Congratulations to Foundation Medicine for a Successful IPO

Our warm congratulations to Foundation Medicine on the important milestone of initial public offerings! Located in Cambridge, Massachusetts, Foundation Medicine is a cancer diagnostic biotech company that enables doctors to recommend treatment options for cancer patients based on their genetic profile. WuXi Corporate Venture Fund participated in its Series B financing in 2012 to help furthering its mission of transforming cancer care through deeper understanding of the underlying genomic changes. On the first day of its market debut on September 24, Foundation Medicine shares rose as much as 89 percent, raising about $106 million to expand its commercial and laboratory operations, and to fund clinical studies. The strong market response reflects great public confidence in the company’s innovative approaches, and the potential of genomics in the treatment of diseases. Congratulations, and we wish Foundation Medicine continued success in bringing better medicines closer to patients! Related Links:  Steve Jobs’ Final Vision Is Coming True Thanks (In Part) To Bill Gates And Google (Source: Business Insider) Foundation Medicine shares rise 89 percent in market debut (Source: Reuters)  Foundation Medicine Expands Series B Financing to $56 Million

Read more


“The China Evolution” -PharmAsia Interview

Richard Soll shared insights with PharmAsia News on China’s pharma evolution, and the transition of WuXi from chemistry services to fully integrated technology and capability platform MORE—>

Read more